The Importance of Preservative Efficacy Testing in Multi Dose Drug
According to pharmacopoeial requirements, multi dose drug products must demonstrate preservative effectiveness against a broad range of microorganisms. This is important because products that are used repeatedly are at risk of microbial contamination each time the container is opened or accessed.
Selecting an appropriate preservative for multi dose drug products can be challenging, as it requires a balance between antimicrobial effectiveness and the stability of biological active ingredients, such as proteins, peptides, or antibodies. This article discusses preservatives that are suitable for multi dose drug products and provides an overview of preservative efficacy testing.
Table of content:
- Choosing the Right Preservative to Maintain the Stability and Safety of Multi Dose Drug Products
- How Is Preservative Effectiveness Demonstrated? Understanding Antimicrobial Testing for Multi Dose Drug Product
Choosing the Right Preservative to Maintain the Stability and Safety of Multi Dose Drug Products
Antimicrobial agents, also known as preservatives, are essential components of multi-dose drug products. They are added to inhibit the growth of microorganisms such as bacteria, yeasts, and molds, maintain product stability throughout storage, and minimize damage to biological active ingredients such as proteins and peptides.
Preservatives can be classified as microbiostatic, which inhibit the growth of microorganisms, or microbicidal, which permanently kill microorganisms. However, the use of preservatives cannot replace the implementation of Good Manufacturing Practices (GMP) and proper aseptic manufacturing processes.
Preservatives are generally categorized into phenolic derivatives, alcohols, benzoic acid derivatives (parabens), and Quaternary Ammonium Compounds (QACs). Each group exhibits a different spectrum of activity against bacteria, yeasts, and molds. However, most of these preservatives are not effective against bacterial spores.
Bacterial spores possess a multilayered protective structure that makes them significantly more resistant to antimicrobial agents than vegetative cells. In addition to serving as a physical barrier, these layers contain enzymes that help protect spores from damage caused by chemical agents.
Commonly used preservatives in biological formulations include phenoxyethanol (PE), methylparaben (MP), propylparaben (PP), benzyl alcohol (BA), phenol (PH), m-cresol (CR), chlorobutanol (CB), and benzalkonium chloride (BAK). Among these, phenoxyethanol is considered particularly promising because it provides effective antimicrobial activity while posing a lower risk of protein destabilization compared with several other preservatives.
An important parameter in preservative selection is the logP value, which indicates the hydrophobicity of a preservative, or its tendency to partition into an oil phase rather than an aqueous phase. This parameter is important because it influences the interaction between preservatives and biological molecules such as proteins and peptides.
Generally, the higher the logP value, the greater the tendency of a preservative to bind to proteins and potentially cause instability, including aggregation or structural alterations. Therefore, preservative selection should carefully balance antimicrobial effectiveness with the need to maintain protein stability.
Read also:
Drug Expiration Date: What Happens Chemically After the Expiration Date?
How Is Preservative Effectiveness Demonstrated? Understanding Antimicrobial Testing for Multi Dose Drug Product
The effectiveness of a preservative is influenced by intrinsic factors related to microorganisms, such as microbial species, cell wall structure, and resistance mechanisms. Some microorganisms can even produce enzymes capable of degrading preservatives, thereby reducing their antimicrobial activity.
Extrinsic factors, including preservative concentration, formulation pH, packaging materials, storage conditions, and interactions with other formulation components, can also affect preservative performance. Therefore, all of these factors should be carefully considered and evaluated to ensure adequate preservative effectiveness.
Preservative efficacy testing (PET), also known as antimicrobial effectiveness testing (AET), is performed to verify that the preservative system in a multi-dose drug product can effectively control microbial growth throughout the product’s period of use. The three major pharmacopoeias commonly referenced for this purpose are the European Pharmacopoeia (Ph. Eur.), the United States Pharmacopeia–National Formulary (USP-NF), and the Japanese Pharmacopoeia (JP).
These pharmacopoeias follow a similar general principle: selected test microorganisms are inoculated into the product, and the number of surviving microorganisms is monitored over a defined period. Preservative effectiveness is then evaluated based on the product’s ability to reduce or inhibit microbial growth.
One key difference among the pharmacopoeias lies in the selection of challenge microorganisms. Ph. Eur. recommends Pseudomonas aeruginosa, Staphylococcus aureus, Candida albicans, and Aspergillus brasiliensis, while USP includes Escherichia coli in addition to these microorganisms for all product categories. JP applies a broader panel by also including Bacillus subtilis and the anaerobic bacterium Clostridium sporogenes.
Another difference concerns product classification. Ph. Eur. divides products into three categories based on the route of administration, whereas USP uses four categories, including a specific category for antacids. In contrast, JP places less emphasis on product categorization and focuses more on the formulation’s ability to remain free from microbial growth.
The testing methods used by the three pharmacopoeias are generally similar and include membrane filtration, plate count procedures, or direct inoculation techniques. However, JP specifically requires the use of a negative control and emphasizes that all testing procedures must be conducted under sterile conditions.
The main distinction in result interpretation lies in the acceptance criteria. Ph. Eur. applies Criterion A and Criterion B, which are based on the level of microbial reduction achieved, while USP establishes different microbial reduction requirements for each product category. JP follows a simpler approach, requiring the absence of microbial growth during the test period for a formulation to be considered adequately protected.
Test First, Claim Safe Later
If your multi dose medicine product is opened and used repeatedly, its safety should not rely on assumptions alone. Through preservative effectiveness testing, brands can prove that their product remains protected from contamination risks during use.
With IML Testing and Research, your product testing can be carried out professionally to support safety, quality, and consumer trust.
Author: Dherika
Editor: Alphi
References
European Pharmacopeia. EP <5.1.3>Efficacy of antimicrobial preservatives.
Japanese Pharmacopeia. JP <19>Preservative effectiveness tests.
Stroppel, L., Schultz-Fademrecht, T., Cebulla, M., Blech, M., Marhöfer, R.J., Selzer, P.M., Garidel, P. (2023). Antimicrobial Preservatives for Protein and Peptide Formulations: An Overview. Pharmaceutics, 15, 563.
United States Pharmacopeia. USP <51>. Antimicrobial effectiveness testing. Rockville, MD.
